ImmunityBio (IBRX) shares gained on Friday after the cancer drug developer announced the successful conclusion of two manufacturing engineering programs designed to validate its Cytokine-Enriched NK ...
Entering a cell and watching its entire inner machinery at work, how DNA is copied, how proteins are assembled, or how it splits in two, has been, for decades, an impossible dream. Now, scientists at ...
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and ...
BERKELEY, CA, March 10, 2026 (EZ Newswire) -- R3 Bio announced the release of its 2026 research report outlining early-stage progress in developing integrated, stem cell-derived biological platforms ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parallel Bio, a biotech company pioneering human-first drug discovery, today announced it has raised $21 million Series A funding, led by AIX Ventures. The round ...
THE WOODLANDS, Texas and HUMMELSTOWN, Pa., March 17, 2026 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced a ...
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...
Quintessence Biotech has launched a bio-separation tool to reduce the manufacturing bottleneck suffered by cell and gene therapies (CGTs), creating the first “living” artificial cell. DACS is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results